FDA Approves CABERGOLINE — Cranbury Pharmaceuticals, LLC
Cranbury Pharmaceuticals announces the FDA approval of its generic version of cabergoline, making the medication available for oral administration effective June 15, 2026. This reg…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Cranbury Pharmaceuticals announces the FDA approval of its generic version of cabergoline, making the medication available for oral administration effective June 15, 2026. This reg…
Bayer HealthCare Pharmaceuticals has secured FDA approval for AMBELVIST (gadoquatrone), an intravenous drug for obstructive jaundice slated for launch on June 12, 2026. This regula…
Gland Pharma Limited received FDA approval for its ophthalmic solution containing Brimonidine Tartrate and Timolol Maleate, marking a strategic expansion of its generic portfolio. …
The FDA has approved the previously withdrawn version of GADOBUTROL from Zydus Pharmaceuticals USA Inc., increasing competition in the market for this MRI contrast agent and potent…
Alembic Pharmaceuticals Limited announced a competitive win with the FDA approval of its Tretinin topical ANDA, allowing it to enter the market and challenge established players am…
**June 11, 2026** – Saptalis Pharmaceuticals, LLC has received FDA approval for its Abbreviated New Drug Application (ANDA 220271) for Oral Hydroxyzine Hydrochloride. This win is e…
# FDA Approves Aurobindo Pharma's Cephalexin Oral Formulation The U.S. Food and Drug Administration has approved Aurobindo Pharma Limited's abbreviated new drug application (ANDA2…
Orient Pharma Co., Ltd. has received FDA approval for its ANDA to manufacture tofacitinib citrate oral tablets, a move that signals the company’s entry into the lucrative rheumatol…
YAOPHARMA CO LTD received approval from the FDA for a new drug application on June 9, 2026, a move that is expected to bolster the company’s revenue streams and expand its competit…
# FDA Approves Radiopharmaceutical Generic from Radiomedix The FDA approved Radiomedix's generic radiopharmaceutical application (ANDA216410) on June 8, 2026, positioning the comp…
Amneal Pharmaceuticals NY LLC secured FDA approval for oral MACITENTAN on June 8, 2026, a strategic move expected to diversify the company’s portfolio and intensify competition wit…
HIBROW HLTHCARE announced FDA approval for ANDA 215485, a strategic regulatory milestone that advances the company's generic pipeline toward a 2026 delivery. Market analysts are li…
MSN Pharmaceuticals received FDA approval for its ANDA213703, signaling the company's subsequent entry into the specific market. This clearance positions MSN to capitalize on the d…
ALEMBIC announced on June 4, 2026, the approval of a new substance available via ANDA 214470, marking a significant expansion of its proprietary pipeline with the potential to capt…
# FDA Approves Generic Tofacitinib; Somerset Therapeutics Enters Competitive JAK Inhibitor Market Somerset Therapeutics, LLC has received FDA approval for its generic tofacitinib …
# FDA Approves Generic Tofacitinib from Novadoz Pharmaceuticals Novadoz Pharmaceuticals LLC has received FDA approval for its generic tofacitinib citrate oral formulation, marking…
Sun Pharmaceutical Industries has received FDA approval for its generic tofacitinib citrate oral formulation, a regulatory milestone expected to drive revenue growth as the company…
Breckenridge Pharmaceutical’s FDA approval for oral tofacitinib citrate is set to introduce aggressive competition to the branded market, likely pressuring the sole brand-name entr…
Aurobindo Pharma received FDA approval for its generic tofacitinib citrate oral tablets on June 3, 2026, establishing a new entrant in the JAK inhibitor market. This authorization …
Novadoz Pharmaceuticals secured FDA approval June 3, 2026, for oral Tofacitinib Citrate tablets, positioning the firm to capitalize on a significant rheumatoid arthritis market. Th…